Comparative Study of Immunogenicity and Safety of Flu-ID Vaccine Versus Flu-IM Vaccine

PHASE3CompletedINTERVENTIONAL

Enrollment

795

Participants

Timeline

Start Date

October 31, 2007

Primary Completion Date

December 31, 2007

Study Completion Date

December 31, 2007

Conditions

Influenza

Interventions

BIOLOGICAL

Flu-ID 15μg

Inactivated Split-Virion Influenza Vaccine for Intradermal Route

BIOLOGICAL

Inactivated adjuvanted Influenza Vaccine

Inactivated adjuvanted Influenza Vaccine for Intramuscular Route

Trial Locations (8)

Antwerp

Massemen

Wilrijk

Angers

Cherbourg

Laval

Seysses

Tiercé

All Listed Sponsors

lead

Sanofi Pasteur, a Sanofi Company

INDUSTRY

NCT00554333 - Comparative Study of Immunogenicity and Safety of Flu-ID Vaccine Versus Flu-IM Vaccine | Biotech Hunter | Biotech Hunter